Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Aligos Therapeutics IncALGS-2.8135.463.56-0.63-146.69%-23.30%53.62$30.25$15.007,388$33.902

Detail of Aligos Therapeutics Inc

 
CEO
Dr. Lawrence M. Blatt MBA, Ph.D.
Employees
68
Industry
Biotechnology
Sector
Healthcare
Market cap
$213M

Company details

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Revenue
Revenue (Rev)
$6.00M
Aligos Therapeutics Inc
ALGS • XNGS • US
$33.902
+33.56 (4,927.90%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$12.07
Margin profit
0.00%
52 week low
$0.35
52 week high
$46.599998
50-day simple moving average
$33.96
200-day simple moving average
$30.25
Percent held by insiders
17.80%
Percent held by institutions
48.86%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Comparison of selected companies

 
%
Price change
ALGS +4,927.90%
eps change
ALGS 0.00%